|
See related Nexavar film-coated tab information |
|
|
|
Manufacturer |
Bayer |
|
Distributor |
Hong Kong: Zuellig/Macau: Firma Chun Cheong |
|
Contents |
Sorafenib |
|
Indications |
Treatment of patients w/ advanced renal cell & hepatocellular carcinomas.
Click to view Nexavar detailed prescribing infomation |
|
Dosage |
400 mg bd.
Click to view Nexavar detailed prescribing infomation |
|
Overdosage |
View Nexavar overdosage for action to be taken in the event of an overdose. |
|
Administration |
Should be taken on an empty stomach (Take on an empty stomach or w/ a low or moderate fat meal. If the patient intends to have a high fat meal, sorafenib should be taken on an empty stomach at least 1 hr before or 2 hr after meals. Swallow whole, do not chew/crush.). |
|
Contraindications |
Pregnancy & lactation.
Click to view Nexavar detailed prescribing infomation |
|
Warnings |
For additional cautionary notes to warn of the potential risk of using the medicine... click to view Nexavar detailed prescribing infomation |
|
Special Precautions |
Dermatological toxicities. Monitor BP wkly during 1st 6 wk of therapy & thereafter; severe or persistent HTN. GI perforation, haemorrhage, cardiac ischemia &/or infarction. Concomitant warfarin, irinotecan, doxorubicin therapy. Temporary interruption in major surgical procedures.
Click to view Nexavar detailed prescribing infomation |
|
Adverse Drug Reactions |
Erythema, exfoliative dermatitis, acne, flushing, increased lipase, increased amylase, mucositis, stomatitis, dyspepsia, dysphagia. Haemorrhage, asthenia, pain, decreased appetite, flu-like illness, pyrexia. Leukopenia, lymphopenia, anaemia, neutropenia, thrombocytopenia. Hypophosphatemia, transient increases in transaminases. Arthralgia, myalgia. Depression.
View ADR Monitoring Form |
|
Drug Interactions |
Warfarin, irinotecan, doxorubicin, substrates of CYP2B6 & CYP2C8, UGT1A1 & UGT1A9, rifampin, St. John's wort, phenytoin, carbamazepine, phenobarb, dexamethasone.
View more drug interactions with Nexavar |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Storage |
View Nexavar storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Nexavar description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Nexavar mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
